These 3 charts show how drastically Valeant has changed over the past year

Valeant reported mixed earnings Tuesday morning, and the stock is up 13%.

“I am continuously encouraged by the commitment of our employees who work hard daily, rebuilding our relationships with prescribers, patients and payors, and regaining the trust of our debt holders and shareholders,” Valeant CEO Joseph Papa said in a release.

The earnings gave an important glimpse into the effects of some of the headlines Valeant’s made over the last year. In particular, its product revenue.

Xifaxan

Xifaxan, the drug that was expected to make $1 billion in 2016, came in at $200 million in revenue for the second quarter 2016 and was the top brand for Valeant this quarter. On the earnings call, Papa said he expects Xifaxan to hit its peak performance in a few years, with the potential to make up to $5 billion.

But not everyone is convinced.

“Based on the top line results, we think Xifaxan was probably weak and not on its way to the $1 billion mark VRX had forecast for 2016,” Wells Fargo analyst David Maris said in a note Tuesday.

Jublia

The $1,000 toe fungus drug got hit hard in Q2, with revenue down almost 70% compared to a year ago. That may be in part because companies like CVS are asking patients to try other, cheaper, solutions first before turning to the Valeant product.